
Barclays has decided to maintain its Overweight rating of Ligand Pharmaceuticals (NASDAQ:LGND) and lower its price target from $165.00 to $157.00.
Shares of Ligand Pharmaceuticals are trading up 1.79% over the last 24 hours, at $92.20 per share.

Barclays has decided to maintain its Overweight rating of Ligand Pharmaceuticals (NASDAQ:LGND) and lower its price target from $165.00 to $157.00.
Shares of Ligand Pharmaceuticals are trading up 1.79% over the last 24 hours, at $92.20 per share.